| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
|
Boral, Anthony L.
|
|
1998
|
42 |
supplement-1 |
p. S3-S21
|
artikel
|
| 2 |
Clinical pharmacology of camptothecins
|
Iyer, Lalitha
|
|
1998
|
42 |
supplement-1 |
p. S31-S43
|
artikel
|
| 3 |
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
|
Sausville, Edward A.
|
|
1998
|
42 |
supplement-1 |
p. S54-S59
|
artikel
|
| 4 |
Clinical trials for advanced gastrointestinal cancers in Japan
|
Shimada, Yasuhiro
|
|
1998
|
42 |
supplement-1 |
p. S80-S84
|
artikel
|
| 5 |
Combined-modality treatment for stage IIIa (n2) non-small cell lung cancer: a national cancer institute intergroup study
|
Ettinger, David S.
|
|
1998
|
42 |
supplement-1 |
p. S71-S74
|
artikel
|
| 6 |
Cooperative oncology groups in Japan: Experience from the Japan Adult Leukemia Study Group
|
Ohno, Ryuzo
|
|
1998
|
42 |
supplement-1 |
p. S93-S97
|
artikel
|
| 7 |
European drug development and its impact on national activities: The Dutch example
|
Pinedo, Herbert M.
|
|
1998
|
42 |
supplement-1 |
p. S98-S101
|
artikel
|
| 8 |
High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
|
Tallman, Martin S.
|
|
1998
|
42 |
supplement-1 |
p. S60-S67
|
artikel
|
| 9 |
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
|
Sugiyama, Yuichi
|
|
1998
|
42 |
supplement-1 |
p. S44-S49
|
artikel
|
| 10 |
National Cancer Institute Clinical Trials Program in Colorectal Cancer
|
Conley, Barbara A.
|
|
1998
|
42 |
supplement-1 |
p. S75-S79
|
artikel
|
| 11 |
Overview of recent topics in clinical pharmacology of anticancer agents
|
Egorin, Merrill J.
|
|
1998
|
42 |
supplement-1 |
p. S22-S30
|
artikel
|
| 12 |
Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients
|
Watanabe, Toru
|
|
1998
|
42 |
supplement-1 |
p. S68-S70
|
artikel
|
| 13 |
Preclinical approach for identifying drug interactions
|
Kamataki, Tetsuya
|
|
1998
|
42 |
supplement-1 |
p. S50-S53
|
artikel
|
| 14 |
Preface
|
Saito, Hidehiko
|
|
1998
|
42 |
supplement-1 |
p. S1
|
artikel
|
| 15 |
Systems of protocol review, quality assurance, and data audit
|
Weiss, Raymond B.
|
|
1998
|
42 |
supplement-1 |
p. S88-S92
|
artikel
|
| 16 |
The Cooperative Groups: Past and future
|
Comis, Robert L.
|
|
1998
|
42 |
supplement-1 |
p. S85-S87
|
artikel
|
Tijdschrift beschrijving